These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1306 related articles for article (PubMed ID: 34449181)

  • 21. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
    Bansal S; Canziani MEF; Birne R; Anker SD; Bakris GL; Filippatos G; Rossing P; Ruilope LM; Farjat AE; Kolkhof P; Lage A; Brinker M; Pitt B
    BMJ Open; 2024 Mar; 14(3):e076444. PubMed ID: 38508632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
    Rossing P; Burgess E; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Gillard P; MacIsaac RJ; Wainstein J; Joseph A; Brinker M; Roessig L; Scott C; Bakris GL;
    Diabetes Care; 2022 Apr; 45(4):888-897. PubMed ID: 35061867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
    Agarwal R; Tu W; Farjat AE; Farag YMK; Toto R; Kaul S; Lawatscheck R; Rohwedder K; Ruilope LM; Rossing P; Pitt B; Filippatos G; Anker SD; Bakris GL;
    Ann Intern Med; 2023 Dec; 176(12):1606-1616. PubMed ID: 38048573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
    Flack JM; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Adler SG; Fried L; Jamerson K; Toto R; Brinker M; Farjat AE; Kolkhof P; Lawatscheck R; Joseph A; Bakris GL;
    Kidney Med; 2023 Dec; 5(12):100730. PubMed ID: 38046911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
    Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
    Filippatos G; Anker SD; Pitt B; McGuire DK; Rossing P; Ruilope LM; Butler J; Jankowska EA; Michos ED; Farmakis D; Farjat AE; Kolkhof P; Scalise A; Joseph A; Bakris GL; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):85-93. PubMed ID: 36251465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
    Bakris GL; Ruilope LM; Anker SD; Filippatos G; Pitt B; Rossing P; Fried L; Roy-Chaudhury P; Sarafidis P; Ahlers C; Brinker M; Joseph A; Lawatscheck R; Agarwal R;
    Kidney Int; 2023 Jan; 103(1):196-206. PubMed ID: 36367466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].
    Scheen A; Delanaye P
    Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann JFE; Bakris G; Baeres FMM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R;
    N Engl J Med; 2024 Jul; 391(2):109-121. PubMed ID: 38785209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
    Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
    Koya D; Anker SD; Ruilope LM; Rossing P; Liu Z; Lee BW; Lee CT; Scott C; Kolkhof P; Lawatscheck R; Wang L; Joseph A; Pitt B;
    Am J Nephrol; 2023; 54(9-10):370-378. PubMed ID: 37708857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
    Agarwal R; Joseph A; Anker SD; Filippatos G; Rossing P; Ruilope LM; Pitt B; Kolkhof P; Scott C; Lawatscheck R; Wilson DJ; Bakris GL;
    J Am Soc Nephrol; 2022 Jan; 33(1):225-237. PubMed ID: 34732509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 66.